Skip to main content
. Author manuscript; available in PMC: 2022 Apr 14.
Published in final edited form as: Vaccine. 2020 Mar 12;38(16):3261–3270. doi: 10.1016/j.vaccine.2020.02.078

Figure 3.

Figure 3.

Impact of varying vaccine efficacy and congenital transmission risk on the incremental cost-effectiveness ratio (ICER) of a therapeutic vaccine given to pregnant women to prevent congenital transmission with (A) $50 vaccination from the third-party payer perspective, (B) $50 vaccination from the societal perspective, (C) $200 from the third-party payer perspective, and (D) $200 from the societal perspective. An ICER of 0 indicates that the vaccination strategy would be economically dominant (i.e., provides cost savings and positive health benefits); ICERs >$60,000/disability-adjusted life year (DALY) averted are not shown.